Astera Labs Grew Revenue 153.6% in Q3, Yet Analysts Cut Targets

Astera Labs reported Q3 revenue of $584.9 million, up 153.6% year over year, and analysts responded by cutting their price targets. That contradiction frames the current state of the AI semiconductor trade better than any survey could.

The Nasdaq-listed connectivity chipmaker beat the $550.8 million analyst consensus. Adjusted earnings per share came in at $1.32, up more than 100% and above consensus by more than 10%. Growth came from the Scorpio product line, the company's newest and now largest family. Scorpio parts are smart fabric switches that link large GPU clusters into single, efficient computing units. The line has already passed a $1 billion annual run-rate, according to the company, and management expects it to accelerate next year.

What did the margins show?

Gross margin compressed. The market looked past that. GAAP operating income rose to $179.1 million from $55.4 million a year earlier. Adjusted net income climbed to $243.4 million from $88.2 million. Operating efficiency and spending control did the work that pricing could not.

Guidance was strong. Management guided Q4 revenue to $730 million to $750 million and adjusted EPS of $1.62 to $1.66. The low ends of both ranges sit above prior analyst expectations. That guidance may still prove conservative, given the company's position in PCIe Gen 6 switching. The company claims an early lead in high-volume production of that technology. A claim is not a shipment figure, and the source provides no unit numbers to verify it.

Why cut targets after a beat?

Analysts cited valuation, not operations. The stock trades at a P/E of 75.98 on a current price of $190.71, near the low end of its 52-week range of $97.89 to $499.48. Most analysts reduced their targets after the print. Most also kept a bullish long-term view. The average target of $320.85, based on 23 ratings, implies roughly 68% upside. That average has climbed about 77% over the past year, even as the individual targets moved down. The spread is wide: forecasts run from $153 to $460.

Institutions own more than 60% of shares. They have bought on balance every quarter since the IPO through early Q4 2026, according to the source. That accumulation could reverse. If institutions sell, the selling adds momentum to the decline. The company's profitability and market position may limit that risk, but nothing in the data guarantees it.

The source also draws a technical-analysis frame. Elliott Wave patterns in Astera Labs and Credo Technology Group charts suggest two scenarios, it argues. Either the AI boom has ended and both stocks stay down, or the build-out continues, sentiment recovers, and the current cycle becomes the first stage of a larger move to new highs before the end of next year. Chart patterns are not fundamentals. The source presents both outcomes as plausible and commits to neither.

Design wins versus sales

One distinction in the report deserves emphasis. Astera Labs holds multiple design wins across numerous customers and end markets. A design win is not a sale. It creates a multi-year revenue opportunity only as customers adopt the technology and scale production. Some programs could generate substantial incremental revenue. The source quantifies none of this. The $1 billion Scorpio run-rate is the only hard demand figure on the table.

The broader context matters here. Results from AMD, onsemi, Oracle, and NXP Semiconductors point the same direction: AI demand is strong, broad-based, and accelerating on next-generation product ramps. The market response to that demand has cooled anyway. Investors are rotating from broad AI speculation toward a smaller group of companies with tangible results and multi-year design wins. Profitable companies are being punished alongside unprofitable ones, the source argues, and that divergence should correct over coming quarters on performance. That is a forecast, not a fact.

Astera Labs carries a Moderate Buy consensus rating. Whether the stock re-rates depends on Scorpio's ramp and on Q4 delivery against that $730 million to $750 million guide; miss either, and the valuation case turns from a reason to trim targets into a reason to leave.